Pharmacogenomic testing, often shortened to PGx, looks at genes that affect how your body processes medications. ClarityX sells that testing directly to you. GeneSight, from Myriad Genetics, sells it through your clinician.
That one structural difference drives nearly everything else here: what you pay, whether insurance touches it, and how likely the result is to change a prescription.
Key Takeaways
- GeneSight is clinician-ordered only. Myriad bills insurance, Medicare, and Medicaid, and its cost page lists a $330 self-pay option for anyone who wants to skip billing.
- ClarityX does not accept health insurance. Mindwell lists at $399 and Max Rx at $499, self-pay, though both are eligible for flexible spending account (FSA) and health savings account (HSA) funds.
- ClarityX’s two kits genotype the same 39 genes. The $100 gap buys a wider interpretation report, not more DNA.
- ClarityX does not name its laboratory. No lab name, CLIA number, or CAP certificate ID appears anywhere on its site.
- The clinical evidence is mixed. The two largest trials in this category both missed the outcome patients care about most.
- Neither test is FDA authorized. The only consumer PGx report that is covers select variants in three genes, and it belongs to 23andMe.
Quick Verdict
Choose GeneSight if you have a prescriber involved in your care. It is ordered by a registered clinician, so the result lands in a chart and gets read by someone who knows your history. Myriad bills insurance and Medicare, and patients on Medicare Part B, Medicare Advantage, or Medicaid typically pay nothing out of pocket. Anyone else can take the flat $330 self-pay option.
Choose ClarityX if no clinician will order testing for you, or if your questions run past psychiatric medications. ClarityX uses a network of physicians licensed in 50 states to authorize your order, so you do not need your own prescriber to buy. That convenience costs real money, and no insurance offsets it.
Choose neither yet if you are hoping a test will name the antidepressant that will work for you. No panel on the market does that, and the trial evidence explains why. For the kit-level detail on the direct-to-consumer side, see our ClarityX review.
How You Order Each One
GeneSight cannot be bought directly. Myriad’s language is unambiguous: the test must be ordered by a registered clinician. You raise it at an appointment, your prescriber decides whether it is warranted, and the cheek swab is collected through that clinical relationship.
ClarityX runs the direct-to-consumer telehealth model instead. You buy the kit, and a network physician licensed in your state reviews and authorizes the order at checkout. There is no clinic visit and no blood draw.
The kit is an at-home DNA collection, and the lab steps behind it match how DNA testing works generally. ClarityX describes it as a cheek swab on some pages and a saliva sample on others, so confirm which at order. Results arrive in the ClarityX patient portal, typically 5 to 10 business days after the lab receives your sample. Only the person who activated the kit can open them.
Provenance matters more than it sounds. A test your psychiatrist ordered is part of your medical record. A test you bought, authorized by a physician you will never meet, is a PDF.
What Each Panel Actually Covers
ClarityX Mindwell and Max Rx genotype an identical 39 genes. Both product pages publish the same list across six categories. Those include drug metabolism genes such as CYP2D6, CYP2C19, and CYP2B6, plus transport genes such as SLCO1B1. They also cover response-signal genes such as HTR2A and COMT, and safety flags such as DPYD, TPMT, NUDT15, and several HLA alleles.
What separates the two kits is report breadth. Mindwell interprets 120+ mental health medications across depression, anxiety, ADHD, bipolar disorder, insomnia, pain, and addiction. Max Rx interprets 285+ prescription medications, adding cardiology, endocrinology, oncology, neurology, and more. Same DNA, wider translation.
ClarityX publishes no upgrade path between the two, so choose the tier you want up front.
GeneSight is psychiatry-focused by design. Its report spans antidepressants, anxiolytics and hypnotics, antipsychotics, mood stabilizers, and stimulants. It draws on both pharmacokinetic genes (how fast you clear a drug) and pharmacodynamic genes (how your receptors respond). That is narrower than Max Rx, in the therapeutic area with the most published evidence.
If you are still weighing categories rather than brands, our roundup of DNA tests for health is the wider view.
Price and Insurance
Run the insurance question before you compare list prices, because it decides more of the cost than either brand’s pricing page does.
GeneSight: Myriad bills insurance, Medicare, and Medicaid. Patients on Medicare Part B, Medicare Advantage, or Medicaid typically pay $0 out of pocket. The cost page states that all patients are eligible for a reduced self-pay option of $330, and that 98% of patients pay $330 or less. A financial assistance program tied to federal poverty guidelines exists, but excludes most federally funded plans.
ClarityX: ClarityX states plainly that it does not accept health insurance, explaining that coverage is inconsistent and denials leave patients with surprise bills. Mindwell lists at $399 and Max Rx at $499. Both are eligible for pre-tax health spending funds, and ClarityX provides an itemized receipt.
ClarityX also runs time-limited promotions. A 25% code was live when we checked, ending August 24. Plan around list price, because a sale is not a price.
The pharmacist consultation is a paid add-on too, booked through the patient portal. Budget for it if you want someone to walk you through a dense report.
What the Evidence Really Shows
Both tests sit on the same body of research, so this applies to either purchase.
GUIDED (2019) missed its primary endpoint. This was GeneSight’s own 8-week randomized trial in 1,167 patients with major depression who had already failed at least one medication. Mean symptom improvement on the HAM-D17 scale at week 8 was 27.2% in the guided arm versus 24.4% in treatment as usual, with p = 0.107. That is not a statistically significant difference.
The secondary outcomes did separate: response 26.0% versus 19.9% (p = 0.013) and remission 15.3% versus 10.1% (p = 0.007). Marketing quotes those as roughly 30% and 50% relative improvements. In absolute terms they are about 6 and 5 percentage points, in a trial whose main question came back negative.
PRIME Care (JAMA, 2022) is the trial to read. It enrolled 1,944 veterans with major depression across 22 VA medical centers. It ran 24 weeks, was not industry funded, and had two co-primary outcomes that diverged.
The prescribing outcome was strongly positive. In the first 30 days, 59.3% of the PGx arm received a medication with no predicted drug-gene interaction. Usual care managed 25.7%, a risk difference of 33.6%. Handing a clinician a genotype report clearly changes what they prescribe.
The symptom outcome was small and did not last. Pooled across 24 weeks, remission favored the tested arm with an odds ratio of 1.28 and an absolute difference of 2.8 percentage points. At 24 weeks specifically there was no significant difference: 17.2% versus 16.0%, p = 0.45. The authors’ own wording is the honest summary — test results had “small nonpersistent effects on symptom remission.”
The meta-analyses look better, and the caveats are load-bearing. A 2024 umbrella review found patients on PGx-guided medication were 41% to 78% more likely to reach remission. They were 20% to 49% more likely to respond. That range is wide because most underlying studies were industry funded, and none properly blinded the treating clinician. In an unblinded trial with a subjective outcome, expectation is hard to separate from drug effect.
CPIC is where the real signal lives. The Clinical Pharmacogenetics Implementation Consortium publishes gene-drug prescribing guidelines and grades each pair. Level A means genotype should change prescribing. CPIC has Level A guidance for CYP2D6, CYP2C19, and CYP2B6 with serotonin reuptake inhibitors and tricyclic antidepressants.
The pharmacodynamic markers are a different story. CPIC states directly that the data for the serotonergic receptor markers do not support their clinical use in antidepressant prescribing. HTR2A, HTR2C, DRD2, GRIK4, ADRA2A, and COMT all sit on ClarityX’s panel under “response signals” without Level A backing. For MTHFR, the American College of Medical Genetics and Genomics has reaffirmed that testing common polymorphisms lacks evidence for routine clinical use.
So the mechanism by which either test can help is narrow and real. It identifies poor and ultrarapid metabolizers at CYP2D6 and CYP2C19. That explains a subset of people who get side effects at normal doses, or get no benefit at all. It also flags high-stakes safety pairs that prevent harm: DPYD with fluoropyrimidine chemotherapy, TPMT and NUDT15 with thiopurines, HLA-B*15:02 with carbamazepine.
What neither panel can do is rank antidepressants by how well they will work for you. If you want help reading a result you already have, a genetic counselor or a pharmacogenomics pharmacist is worth more than a wider panel.
Where 23andMe’s FDA-Authorized Report Fits
Neither ClarityX nor GeneSight has FDA marketing authorization. Both run in CLIA-certified laboratories, the normal regulatory home for clinical PGx panels. That is a quality standard, not a review of whether the test predicts anything.
The one consumer pharmacogenetics report that has been through FDA is 23andMe’s, granted de novo authorization on October 31, 2018. It is also the narrowest product mentioned here: select variants in three genes, CYP2C19, DPYD, and SLCO1B1, with drug-level insight limited to a handful of medications.
FDA attached hard labeling limits, and 23andMe posts them. The reports do not describe whether a person will respond to a therapeutic. Certain DPYD and CYP2C19 results should be confirmed by independent testing your own provider orders. Our walkthrough of 23andMe health results covers what that kind of report contains.
Breadth and FDA review run in opposite directions here. A three-gene authorized consumer report and a 39-gene unauthorized clinical panel answer different questions, which is also why test accuracy depends on what you are measuring.
Who Should Pick Which
Pick GeneSight if you are working with a prescriber, or you are on Medicare, Medicare Advantage, or Medicaid. The clinician-ordered model is a barrier to buying and an advantage afterward, because the result arrives inside your care rather than alongside it.
Pick ClarityX Mindwell if no clinician will order testing for you, your questions are psychiatric, and you have pre-tax health funds to spend. At $399 you get the full 39-gene genotype with a 120+ medication mental health report.
Pick ClarityX Max Rx if your prescribing questions run past psychiatry into cardiology, oncology, pain, or endocrinology, and the extra $100 for 285+ medications is worth it. It is the same genotype, so buy this tier for the report, not for better data.
Skip both for now if your only goal is finding the right antidepressant faster, or if you might change a medication on your own after reading a report. ClarityX’s own disclaimer says never to start, stop, or change medication without your provider.
Whichever you buy, bring the actual report to your next appointment. Ask your prescriber which flagged genes carry real guidance for the medications you take, and which are lower-confidence markers.
Privacy and Lab Transparency
Privacy concerns are a real product dimension here. ClarityX’s privacy policy, effective January 31, 2025, says test kits containing your DNA sample are destroyed once genetic information is produced. On selling data, read the exact wording. Precision Sciences will not sell, lease, or rent your identifiable individual information “without your explicit consent.”
That is a no-sale-without-consent commitment scoped to identifiable data, not an absolute prohibition, even though the FAQ states it more flatly. The policy specifies no retention period for the derived genetic data, and describes no research opt-in or opt-out.
There is also a HIPAA seam worth understanding. ClarityX badges “HIPAA certified” on product pages, but no such certification exists — HIPAA is a compliance obligation, not a credential any body issues. Whether you get HIPAA’s patient rights depends on whether your result lands in a covered entity’s record, which for a kit you bought yourself it may not.
The gap that gives us the most pause is the laboratory. ClarityX says testing is performed in a lab that is CLIA-certified and CAP-accredited, but publishes no lab name, no CLIA number, and no CAP certificate ID. If you need to document the performing laboratory for a benefits administrator or a records request, you would have to ask customer service. GeneSight is a Myriad Genetics product, so the company behind the test is named.
The Bottom Line
GeneSight is the better test for most people who can get it. Insurance coverage removes the cost barrier and clinician ordering removes the interpretation barrier. Both matter more than panel size, because the actionable genes, CYP2D6 and CYP2C19, are on every serious panel here.
ClarityX earns its place when the clinician route is closed to you. Mindwell at $399 gets you the same 39-gene genotype as the $499 Max Rx, so pick the tier by the report you want. Expect a metabolism profile and a set of safety flags you can bring to a prescribing conversation, not a shortlist of medications that will work. Our full ClarityX review has the kit-level detail.
